newsfilter
← Latest News
GlobeNewswire·

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients